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African Americans have an increased risk of developing various progressive CKDs, including focal and segmental glomerulosclerosis, hypertension-related nephropathy, sickle cell disease nephropathy, and HIV-associated nephropathy.[@bib1], [@bib2], [@bib3] This risk has been attributed to *APOL1* genetic variants.[@bib4], [@bib5] *APOL1* functions as a part of the innate immune system, and its circulating form bound to high-density lipoproteins protects humans and higher primates against *Trypanosome* species.[@bib6] The risk alleles responsible for kidney disease are 2 coding variants in the last exon (exon 7) of the *APOL1* gene. The first allele, G1, consists of 2 amino acid substitutions (Ser342Gly and Ile384Met) in almost complete linkage disequilibrium. The second allele, G2, represents a 6--base pair (bp) deletion resulting in loss of 2 amino acids (Asn388-Tyr389del) in the same functional domain as G1.[@bib5], [@bib6], [@bib7], [@bib8] These variants confer a selective advantage to Africans carrying 1 or 2 alleles in some areas where sleeping sickness (human African trypanosomiasis) and possibly other infectious diseases are endemic.[@bib4], [@bib7], [@bib9] DRC is one of the countries most affected by sleeping sickness.[@bib4]

Although the protective role of *APOL1* against *Trypanosome* is well known (endocytosis by the parasite with subsequent insertion into the membranes and pore formation lead to lysis of the parasite),[@bib10] the mechanisms of kidney damage associated with HRGs remain obscure.[@bib11] Overexpression of *APOL1* G1 and G2 variants in podocytes, using cell and animal models, has been shown to do the following: induce a cytotoxic effect by apoptosis, necrosis, or inflammatory cell death (pyroptosis)[@bib12], [@bib13]; disrupt autophagic flux[@bib12]; alter mitochondrial function[@bib12], [@bib14]; stimulate potassium efflux[@bib15]; and stress response pathways.[@bib15] However, to what extent these mechanisms are involved in humans is still unknown. Moreover, whether an environmental or genetic "second hit" is always required to induce damage associated with HRG is a matter of debate,[@bib16], [@bib17] especially given that \<15 of 100 HRG carriers are predicted to develop end-stage renal disease.[@bib18]

Nevertheless, although evolving epidemiologic data support an association between *APOL1* HRG and progressive CKD among African Americans,[@bib7], [@bib8], [@bib16], [@bib19] information is limited in the African population, and no data are available in African children. A few studies indicate that G1 and G2 alleles are most common in West Africa, with the highest frequencies occurring in Ghana and Nigeria (G1, \>40%; G2, 6%--24%).[@bib4], [@bib16] The most recent *APOL1* variants distribution map shows the scarcity of *APOL1*-related genotypic data in Central Africa, highlighting the critical need for extensive genotyping among diverse African ethnic groups.[@bib4]

HIV infection was identified as an extremely potent risk factor for *APOL1-*related CKD.[@bib8] For a person with HIV, *APOL1* HRG increases the risk of developing HIV-associated nephropathy by 29- to 89-fold.[@bib8], [@bib16] In sub-Saharan Africa, where HIV infection and its complications are a substantial healthcare problem, policy for early detection of CKD, including HIV-related CKD, is lacking in most settings.[@bib20], [@bib21] In addition, the geographic distribution of *APOL1* risk variants and their association with HIV-related CKD are not well documented in either adults or children, and no reliable data are available for Central Africa. Identifying high-risk individuals or groups, and early detection of CKD, could contribute significantly to developing a rational strategy to prevent or slow the progression to end-stage renal disease of *APOL1* kidney disease. This strategy is particularly important in resource-limited settings where renal replacement therapy is generally unavailable or financially inaccessible.

This study aimed to describe the prevalence of *APOL1* risk variants in a pediatric population of DRC and to evaluate the association between HRG and a marker of early kidney damage in both the general pediatric population and a population at risk for *APOL1*-related nephropathy, namely, HIV-infected children.

Methods {#sec1}
=======

Compliance with Ethical Standards {#sec1.1}
---------------------------------

The study was approved by the National Ethical Committee of the Public Health School of the University of Kinshasa, in compliance with the principles of the Helsinki Declaration. A signed, written informed consent form was obtained from parents or legal guardians of children upon recruitment.

Study Design and Participants {#sec1.2}
-----------------------------

This cross-sectional study was conducted from May 2017 to May 2018. In total, 813 participants (≤18 years old), composed of 2 different populations, were enrolled. Using a multi-stage sampling strategy, Congolese children from the general population were recruited in the 4 main districts that make up Kinshasa, the capital of DRC. The participants (n = 412) were recruited from the popular churches at the rate of one church per district, after agreement of church officials was obtained. The choice of these churches was based on their power of mobilization and grouping of children of different ethnicities and social and economic strata. To minimize sample bias, only one sibling was randomly selected per family. The subjects were not related to each other. For the second group, the eligibility criteria were that subjects should be HIV-infected children (n = 401) treated with non-renal toxic antiretroviral drugs following the guidelines for integrated HIV management in DRC (the DRC National AIDS Control Program \[PNLS\])[@bib22] and regularly followed by the main pediatric HIV clinic in each district recognized by PNLS. The study subjects were not related to each other. The study is reported according to the STROBE statement for observational studies.

Clinical and Early-Stage Kidney Disease Assessment {#sec1.3}
--------------------------------------------------

At enrollment, sociodemographic and anthropometric data (age, gender, height, weight, body mass index), and systolic and diastolic blood pressure (SBP, DBP), were collected from all participants. Blood pressure was measured on the right upper arm with participants in a sitting position after 5 minutes of rest, using a calibrated aneroid sphygmomanometer for pediatric patients (WelchAllyn, Hechingen, Germany) at the heart level. Considering the average of 3 blood pressure measurements, hypertension was defined according to the updated definitions of blood pressure categories and stages reported by Flynn *et al.*[@bib23] For HIV-infected children in whom viral load was not available within 6 months prior to recruitment, a viral load quantification was performed using the Abbott m2000rt Real Time HIV-1 assay (Abbott Laboratories, Abbott Park, IL). The lower limit of detection was 40 copies/ml. A high viral load was defined by a copy number \> 1000/ml. Serum creatinine was measured in all participants using an enzymatic method, with a COBAS C111 apparatus (Roche Instrument Center, Rotkreuz, Switzerland). Estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula.[@bib24] Reduced kidney function was defined as eGFR \<60 ml/min per 1.73 m^2^. A first of the morning, fasting, fresh urine sample was collected from each participant. Urinary albumin excretion, expressed as the urinary albumin/creatinine ratio was assessed using an immunoturbidimetric method, with a DCA Vantage Analyzer (Siemens Healthineers Global, Erlangen, Germany). Elevated albuminuria was defined as a urinary albumin/creatinine ratio ≥30 mg/g.

Assessment of *APOL1* Renal Risk Alleles {#sec1.4}
----------------------------------------

DNA was extracted from whole blood samples using Qiagen kits following manufacturer instructions (QIAamp DNA Mini Kit; Qiagen, Venlo, Netherlands) in the genetics laboratory of the University of Kinshasa. The extracted DNA was transferred to the laboratory of Development and Regeneration of KU Leuven (Katholieke Universiteit, Leuven, Belgium) for storage and genotyping. *APOL1* genotyping was performed for 2 renal risk alleles: G1 (coding variants rs73885319A\>G \[p.Ser342Gly\] and rs60910145G\>T \[p.Ile384Met\]) and G2 (6-bp deletion, rs71785313). Exon 7 (883 bp) of *APOL1* was amplified using gene-specific primer pairs (Fw5′-GTCACTGAGCCAATCTCAGC-3′/Rv5′-CATATCTCTCCTGGTGGCTG-3′). Polymerase chain reaction experiments were performed on genomic DNA using GoTaq Green DNA Polymerase (Promega Corporation, Fitchburg, Wisconsin) and consisted of 35 cycles with the annealing temperature of 55 °C. Alkaline phosphatase and exonuclease exoSAP IT (Affymetrix, Santa Clara, CA) were applied for polymerase chain reaction purification. Subsequently, Sanger sequencing was performed with an ABI 3100XL High-Throughput DNA Sequencer (Applied Biosystems, Foster City, CA). *APOL1* HRG was defined by the presence of 2 risk alleles (G1/G1, G2/G2, or G1/G2), and LRG was defined by the presence of 0 or 1 risk alleles.

Statistical Analysis {#sec1.5}
--------------------

Data were analyzed using SPSS for Windows, version 18.00, 2009 (IBM, Chicago, IL). Independent groups were compared using the Student's *t*-test, χ^2^ test, or Fisher's exact test, as appropriate. Determinants of albuminuria were assessed using logistic regression models. To investigate possible confounding variables and collinearity between independent variables, covariates were included in the final model if they were statistically significant in the univariate analysis, or if they were clinically or epidemiologically relevant. ORs were provided with their 95% CIs. A *P* value \<0.05 was considered significant based on a 2-tailed test. A χ^2^ test was used to test the deviation from Hardy-Weinberg equilibrium.

Results {#sec2}
=======

Characteristics of the Study Population {#sec2.1}
---------------------------------------

The general characteristics of the 2 study populations are summarized in [Table 1](#tbl1){ref-type="table"}. In the general population, the mean age, SBP, DBP, and eGFR were 9.0 ± 4.3 years, 101.2 ± 11.6 mm Hg, 61.5 ± 10.1 mm Hg, and 99.1 ± 22.8 ml/min per 1.73 m^2^, respectively. The mean age, SBP, DBP, and eGFR in HIV-infected children were 11.6 ± 4.1 years, 104.2 ± 14.1 mm Hg, 67.4 ± 10.4 mm Hg and 107.0 ± 36.8 ml/min per 1.73 m^2^, respectively. Of 401 HIV-infected children receiving the combined antiretroviral drugs available, 95% were treated by the first-line regimen (zidovudine or abacavir + lamivudine + nevirapine or efavirenz) versus 5% by the second-line regimen (abacavir or zidovudine or tenofovir + lamivudine + lopinavir/ritonavir).Table 1General characteristics of 2 study populationsCharacteristicGeneral population (children), n = 412HIV-infected children, n = 401*P* valueAge (yr)9.0 ± 4.311.6 ± 4.1\<0.001Gender, male193 (46.8)196 (48.9)0.30Height (cm)130.1 ± 22.6140.3 ± 20.6**\<**0.001Weight (kg)30.6 ± 13.334.9 ± 13.8\<0.001BMI (kg/m^2^)17.2 ± 2.716.9 ± 3.00.13SBP (mm Hg)101.6 ± 11.6104.2 ± 14.10.004DBP (mm Hg)61.5 ± 10.167.4 ± 10.4**\<**0.001SBP \> 95th percentile50 (12.0)58 (14.5)0.19DBP \> 95th percentile21 (5.0)39 (9.7)0.01Serum creatinine (mg/dL)0.57 ± 0.160.59 ± 0.210.11eGFR (ml/min per 1.73 m^2^)99.1 ± 22.8107.0 ± 36.8\<0.001eGFR \< 60 ml/min per 1.73 m^2^13 (3.1)26 (6.5)0.02U-ACR ≥30 mg/g40 (9.7)72 (18.0)\<0.001 Microalbuminuria (30--299 mg/g)33 (8.0)71 (17.7)\<0.001 Macroalbuminuria (≥300 mg/g)7 (1.7)1 (0.2)0.07Viral load \>1000 copies/ml---107 (26.6)---At least one *APOL1* risk allele174 (42.2)162 (40.4)0.32High-risk genotype29 (7.0)23 (5.7)0.27 G1/G14 (0.9)5 (1.2)--- G2/G211 (2.6)4 (0.9)--- G1/G214 (3.4)14 (3.5)---Low-risk genotype383 (93.0)378 (94.3)0.27 G1/G084 (20.4)84 (20.9)--- G2/G061 (14.8)55 (13.7)--- G0/G0238 (57.7)239 (59.6)---[^1][^2]

*APOL1* Genotype Distribution in the General Population and in HIV-Infected Children {#sec2.2}
------------------------------------------------------------------------------------

Of 412 children recruited in the general population, 174 (42.2%) participants carried at least one *APOL1* risk allele ([Table 1](#tbl1){ref-type="table"}). Considering all chromosomes, the risk allele frequency was 12.4% for G1 and 10.4% for G2. With regard to risk genotype frequency, *APOL1* sequence analysis revealed 29 participants (7.0%) carrying a HRG (G1/G1, G2/G2, and G1/G2), and LRG frequencies were 57.7%, 20.4%, and 14.8% for G0/G0, G1/G0, and G2/G0, respectively. In HIV-infected children, 23 of 401 (5.7%) participants carried HRG, whereas 239 of 401 (59.6%) carried G0/G0, 84 of 401 (20.9%) carried G1/G0, and 55 of 401 (13.7%) carried G2/G0 genotypes ([Table 1](#tbl1){ref-type="table"}). Genotypes were distributed according to the Hardy-Weinberg equilibrium (*P* \> 0.05), and there was no difference in the distribution between healthy and HIV-infected children.

Prevalence of Elevated Albuminuria and the Association with *APOL1* HRG {#sec2.3}
-----------------------------------------------------------------------

### General Population {#sec2.3.1}

As shown in [Table 1](#tbl1){ref-type="table"}, elevated albuminuria was present in 40 of 412 (9.7%) healthy children, and reduced kidney function was detected in 13 of 412 (3.1%). HIV-infected children were on average 2.6 years older, which explains some differences between the groups. However, a higher number of these children had elevated albuminuria and a decreased eGFR, compared with healthy children, although the mean eGFR was higher in HIV-infected children, possibly due to the hyperfiltration which precedes proteinuria. Mean SBP (*P* = 0.05) and DBP (*P* \< 0.001) were higher in children presenting with elevated albuminuria than in those with normal albuminuria ([Table 2](#tbl2){ref-type="table"}). Univariate analysis of the association between elevated albuminuria and an *APOL1* HRG is shown in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}. As reported in [Table 3](#tbl3){ref-type="table"}, a total of 5 of 29 (17.2%) children who carried *APOL1* HRG presented with elevated albuminuria, compared with 35 of 383 (9.0%) children with LRG (unadjusted OR 2.1, 95% CI 0.6--6.0; *P* = 0.13). Moreover, children carrying HRG (29 of 412) demonstrated higher SBP (*P* = 0.002) and DBP (*P* = 0.01) and lower eGFR (*P* = 0.04) than those with LRG ([Table 3](#tbl3){ref-type="table"}). Multivariate logistic regression analysis showed that SBP \>95th percentile (adjusted OR 2.73, 95% CI 1.16--6.41; *P* = 0.021) emerged as the main independent factor associated with elevated albuminuria ([Table 4](#tbl4){ref-type="table"}).Table 2Descriptive statistics of characteristics of study population by level of albuminuriaCharacteristicGeneral population (n = 412)HIV-infected children (n = 401)U-ACR ≥ 30 mg/g (n=40)U-ACR \< 30 mg/g (n=372)*P* valueU-ACR ≥ 30 mg/g (n=72)U-ACR \< 30 mg/g (n=329)*P* valueAge (yr)9.3 ± 4.59.0 ± 4.20.6712.4 ± 4.011.4 ± 4.10.06Gender, male18 (45.0)175 (47.0)0.4728 (38.9)168 (51.06)0.04BMI (kg/m^2^)16.4 ± 4.116.4 ± 3.3NS16.8 ± 2.816.3 ± 3.110.21SBP (mm Hg)106.5 ± 12.3101.1 ± 11.40.005106.7 ± 13.2103.7 ± 14.20.10DBP (mm Hg)67.3 ± 10.760.9 ± 9.9\<0.00168.6 ± 19.867.2 ± 10.50.59SBP \> 95th percentile11 (20.0)39 (10.5)0.00411 (15.3)47 (14.3)0.47DBP \> 95th percentile5 (12.5)16 (4.3)0.0411 (15.3)28 (8.5)0.06eGFR, ml/min per 1.73 m^2^101.3 ± 29.498.9 ± 22.70.5495.5 ± 25.0110.3± 38.30.002eGFR \< 60 ml/min per 1.73 m^2^2 (5.0)11 (2.9)0.364 (5.5)22 (6.7)0.48Viral load \>1000 copies/ml---------48 (66.7)59 (18.0)\<0.001*APOL1* high- risk genotype5 (12.5)24 (6.4)0.1418 (25)5 (1.5)\<0.001G1/G11 (2.5)3 (0.8)0.334 (5.5)1 (0.3)0.004G1/G22 (5.0)12 (3.2)0.6311 (15.3)3 (0.9)\<0.001G2/G22 (5.0)9 (2.4)0.293 (4.1)1 (0.3)0.010 risk alleles (%)G0/G021 (52.5)215 (57.8)0.6131 (43.0)208 (63.2)0.0021 risk allele (%)14 (35.0)133 (35.7)1.0023 (31.9)116 (35.2)*0.68*G0/G18 (20.0)78 (20.9)1.0014 (19.4)70 (21.3)0.87G0/G26 (15.0)55 (14.8)1.009 (12.5)46 (13.9)0.85[^3]Table 3Sociodemographic characteristics, viral load level, and kidney disease markers in general pediatric population and HIV-infected children by *APOL1* risk genotype statusCharacteristicGeneral population (n = 412)HIV-infected children (n = 401)High-risk genotype (n = 29)Low-risk genotype (n = 383)*P* valueHigh-risk genotype (n = 23)Low-risk genotype (n = 378)*P* valueAge (yr)10.0 ± 4.19.0 ± 4.10.2011.4 ± 3.611.6 ± 4.10.81Gender, male12 (41.4)181 (47.2)0.349 (39.1)187 (49.5)0.22BMI (kg/m^2^)16.5 ± 3.016.4 ± 3.40.8816.9 ± 2.216.8 ± 3.10.87SBP (mm Hg)108.4 ± 11.5101.4 ± 11.40.002102.5 ± 14.2104.3 ± 14.10.55DBP (mm Hg)65.8 ± 11.261.2 ± 9.90.0163.6 ± 9.767.7 ± 10.40.06SBP \> 95th percentile7 (24.1)53 (13.8)0.112 (8.7)56 (14.8)0.32DBP \> 95th percentile4 (13.8)17 (4.4)0.051 (4.3)38 (10.0)0.32Viral load \>1000 copies/ml---------10 (43.5)97 (25.7)0.05eGFR, mL/min per 1.73 m^2^90.9 ± 21.799.6 ± 22.80.04103.2 ± 32.9107.7 ± 37.00.57eGFR \< 60 mL/min per 1.73 m^2^1 (3.4)12 (3.1)0.612 (8.7)24 (6.3)0.45U-ACR ≥30 mg/g5 (17.2)35 (9.0)0.1318 (78.3)54 (14.3)\<0.001Microalbuminuria (30--299 mg/g)4 (13.8)29 (7.5)0.2717 (73.9)54 (14.3)\<0.001Macroalbuminuria (≥300 mg/g)1 (3.4)6 (15.6)0.401 (4.3)0 (0.0)---[^4][^5]Table 4Determinants of elevated albuminuria in multivariate logistic regression analysisVariableCoefficient (standard error)Z-scoreAdjusted OR (95% CI)*P* valueDependent variable: Albuminuria General population (n = 412) Age--0.005 (0.046)--0.1170.99 (0.90--1.08)0.90 Gender--0.048 (0.343)--0.1400.95 (0.48--1.87)0.89 BMI0.040 (0.065)0.6211.04 (0.92--1.18)0.53 DBP \> 95th percentile0.534 (0.614)0.8691.70 (0.51--5.68)0.38 SBP \> 95th percentile1.006 (0.435)2.3122.73 (1.16--6.41)0.02 eGFR \< 60 ml/min per 1.73 m^2^0.682 (0.798)0.8551.98 (0.41--9.44)0.39 *APOL1* high-risk genotype0.493 (0.552)0.8911.63 (0.55--4.83)0.37 HIV-infected children (n = 401) Age0.024 (0.048)0.5091.02 (0.93--1.12)0.61 Gender--0.370 (0.326)--1.1340.69 (0.36--1.30)0.25 BMI--0.054 (0.063)--0.8650.95 (0.84--1.07)0.38 DBP \> 95th percentile0.858 (0.497)1.7262.36 (0.89--6.25)0.08 SBP \> 95th percentile0.219 (0.469)0.4671.24 (0.49--3.12)0.64 eGFR\< 60 ml/min per 1.73 m^2^--0.367 (0.716)--0.5130.69 (0.17--2.82)0.60 Viral load \>1000 copies/ml2.336 (0.342)6.82410.34 (5.29--20.23)\<0.001 *APOL1* high-risk genotype3.483 (0.605)5.75632.56 (9.94--106.58)\<0.001[^6]

### HIV-Infected Children {#sec2.3.2}

Elevated albuminuria was detected in 72 of 401 (18.0%) HIV-infected children, and reduced kidney function was detected in 26 of 401 (6.5%), as shown in [Table 1](#tbl1){ref-type="table"}. In the univariate analysis, male gender (*P* = 0.04), eGFR (*P* = 0.002), *APOL1* HRG (*P* \< 0.001), and high viral load (*P* \< 0.001) were associated with elevated albuminuria ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). Regarding HIV-infected children carrying *APOL1* HRG (n = 23), 10 of 11 (90.9%) patients with a viral load of \>1000 copies/ml presented with elevated albuminuria, and 8 of 12 (66.7%) children with a viral load of \<1000 copies/ml had elevated albuminuria (OR 5.0, 95% CI 0.36--270.34; *P* = 0.32). Multivariate logistic regression analysis showed that *APOL1* HRG (adjusted OR 32.56, 95% CI 9.94--106.58; *P* \< 0.001) and a high viral load (adjusted OR 10.34, 95% CI 5.29--20.23; *P* \< 0.001) were the only independent risk factors associated with elevated albuminuria ([Table 4](#tbl4){ref-type="table"}). This strong association between *APOL1* HRG and elevated albuminuria in HIV-infected children is further highlighted in [Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}, which show that almost 78% of HIV-infected children carrying *APOL1* HRG presented with albuminuria, compared with 14.3% of those carrying LRG (unadjusted OR 21.60, 95% CI 7.25--76.62; *P* \< 0.001).Figure 1Proportion (%) of children who presented elevated albuminuria among those carrying the *APOL1* high-risk genotype. Higher proportions of HIV-infected patients who carried the *APOL1* HRG had elevated albuminuria compared to those with the low-risk genotype (78% of HIV-infected patients carried an APOL1 high-risk genotype versus 14% who had a low-risk genotype), whereas no difference in the occurrence of elevated albuminuria was observed between subjects carrying a high-risk versus low-risk genotype in the general population.

Discussion {#sec3}
==========

To our knowledge, the present study is the first to describe, in an African pediatric population, the prevalence of *APOL1* risk variants and investigate the association between *APOL1* HRG and early-stage kidney disease in both HIV-infected and healthy children.

Prevalence of *APOL1* Risk Variants {#sec3.1}
-----------------------------------

We found a higher prevalence of *APOL1* HRG (7.0%) in the general population in DRC than was previously assumed. Moreover, the allele prevalence of G1 (12.4%) and G2 (10.4%) was also much higher than that previously reported (G1: 0%; G2: 3.8%).[@bib1] This difference can be attributed to the increased sample size. Indeed, Kopp *et al.*[@bib1] reported the worldwide frequency distribution of *APOL1* variants G1 and G2 in DNA samples from 1024 individuals of various ethnicities, while only 15 individuals were recruited from DRC. However, the most recent study describing the frequency distribution of G1 and G2 variants, in Africa and worldwide,[@bib4], [@bib7] showed the prevalence of G2 in African Americans (13%--15%) to be similar to that found in our study. The prevalence of the G1 allele in our study population was lower than that reported in African Americans (20%--22%) and much lower than the prevalence detected in Nigeria and Ghana (\>40%). Western Africa has been reported to be the epicenter of *APOL1* variants.[@bib4], [@bib5], [@bib7] It has been hypothesized that the *APOL1* variants arose in the past 10,000 years on sub-Saharan African chromosomes, likely in West Africa, where they have been subjected to intense positive selection.[@bib4], [@bib25], [@bib26] The high prevalence of G1 and G2 alleles in African Americans is explained by the fact that their ancestry is predominantly from the ethnicities of the Niger-Kordofanian language group, which is most common in Western Africa.[@bib27] This explanation is in line with the *APOL1* G1 and G2 frequency along the Atlantic coast of Africa, which was the source of the Atlantic slave trade.[@bib4], [@bib27] The same reason might explain the slight difference between the prevalence of *APOL1* HRG detected in the present study (7.0%) and that found in African Americans, which ranges[@bib4], [@bib7] from 10% to 15%. In the present study, the prevalence of *APOL1* HRG G1/G1 (1.2%) and G2/G2 (0.9%) in HIV-infected children was consistent with the trend commonly reported in other populations,[@bib4] whereas the prevalence of HRG G2/G2 (2.6%) was higher than that of G1/G1 (0.9%) in the general population. Despite the precautions taken in selecting participants (1 sibling randomly selected per family), some degree of selection bias may have persisted and could have influenced the prevalence of the G1/G1 and G2/G2 genotypes in the general population. In addition, absolute numbers should be interpreted with caution due to the small study population. However, these issues highlight the critical need for extensive sampling to perform genotyping among diverse African ethnic groups in order to identify the extent of genetic diversity. In the present study, participants were comprised of a mixed population originating from 4 main linguistic groups representative of more than 200 different ethnic groups identified in DRC. Nevertheless, the observed trend in prevalence should be confirmed in a larger population.

Prevalence of Markers of Kidney Disease {#sec3.2}
---------------------------------------

The prevalence of elevated albuminuria was 18%, and reduced renal function was present in 6.5% of HIV-infected children recruited in the present study. Comparable results have been reported in Tanzania, where albuminuria (20.4%) and eGFR \<60 ml/min per 1.73 m^2^ (5.8%) were detected in HIV-infected children.[@bib28] This finding is in line with several other studies around the world, using different methodologies and patients' clinical profiles, showing that microalbuminuria is a common and early marker of kidney damage in HIV-infected children.[@bib20], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33] Data from the current study showed that systolic hypertension was not associated with elevated albuminuria in HIV-infected children, as well as in the general pediatric population. This result is consistent with previous observations that in kidney disease associated with HIV, high blood pressure is very rare. This rarity can be partially explained by fluid losses, as in the case of chronic diarrhea, for example, or by adrenal insufficiency due to adrenalitis.[@bib34], [@bib35] On the other hand, increased SBP and DBP and decreased eGFR demonstrated in healthy children carrying HRG suggest that increased odds of having hypertension and kidney disease associated with *APOL1* can be already present in childhood. Although some data support a higher incidence of hypertension and kidney disease among *APOL1* HRG compared to LRG carriers,[@bib36], [@bib37] whether this increased risk is due to the underlying CKD or is present independently[@bib38] is unclear. Our data may be useful in discussing this important issue. However, the noticed increased SBP and DBP and decreased eGFR do not appear to be in the same range with established literature data in other populations. As this is the first report in African children carrying *APOL1* HRG, confirmation of the present findings in a much larger African population is required.

Determinants of Elevated Albuminuria {#sec3.3}
------------------------------------

In our study, *APOL1* HRG and a high viral load were found to be significant independent contributors to elevated albuminuria in HIV-infected children. Indeed, HIV-infected children who carried *APOL1* HRG had almost 22-fold increased odds of having elevated albuminuria compared with those carrying an LRG. This correlation between *APOL1* HRG and kidney disease in HIV-infected patients is stronger than that reported in African-American children with perinatal HIV infection[@bib16] and is consistent with data reported in HIV-infected women in the United States.[@bib39] On the other hand, only 18% of HIV-infected children with elevated albuminuria carried an HRG, suggesting that additional genetic or environmental factors might contribute to the development of kidney disease among HIV-infected children. A high viral load was found to be significantly associated with elevated albuminuria in our study. This result is consistent with several previous studies in Africa and around the world.[@bib19], [@bib28], [@bib32], [@bib39], [@bib40] The strong association between viral load and albuminuria in HIV-infected children treated with antiretroviral drugs may emphasize that albuminuria can be used as an indicator of HIV treatment failure or resistance. In terms of the presence of elevated albuminuria in HIV-infected children carrying HRG, no statistically significant difference was observed between patients with high viremia (viral load \>1000 copies/ml) and those whose viral load was \<1000 copies/ml. In contrast, in a longitudinal study, Estrella *et al.*[@bib41] described the association between APOL1 risk alleles and kidney function by extent and degree of HIV viremia suppression. Given the large but nonsignificant OR observed in our study, we assume that the study was underpowered to detect such an association. A longitudinal study is ongoing and will show an evolution of albuminuria and kidney function in our population.

This study is one of the few in Africa that meets the critical need for extensive sampling to perform genotyping among diverse African ethnic groups. Particularly, Central Africa is highlighted as a gap in the most recent map of the distribution of *APOL1* risk variants in Africa.[@bib4] However, the study has some limitations. The cross-sectional design could not determine whether a direct cause--effect relationship explains the associations found. Furthermore, the prevalence of the markers of kidney disease reported in our study might be slightly overestimated, despite the precautions taken to minimize the bias due to a single measurement of albuminuria and creatinine. These measures consisted of the collection of a first of the morning, fresh fasting urine sample in order to exclude orthostatic proteinuria and the effect of meals, and to control factors known to affect the occurrence of albuminuria, such as fever, urinary tract infection, and/or hematuria.

Therefore, determining the longitudinal trajectory of albuminuria, hypertension, and CKD associated with *APOL1* risk variants is needed. For this purpose, a prospective follow-up including all children who presented with albuminuria as well as those with HRG is in progress. Nevertheless, the findings of the present study are of importance in defining preventive and therapeutic strategies against *APOL1*-related kidney disease.

Conclusion {#sec3.4}
==========

This study is the first to report the high burden of *APOL1* risk variants in a pediatric population from Central Africa and is one of the few studies showing the association of *APOL1* HRG with early kidney damage in the general pediatric population and HIV-infected children. Data from the present study showed that carriers of HRG have increased odds of exhibiting early kidney disease, and additional infection with HIV dramatically increases this probability.
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[^1]: BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; U-ACR, urine albumin-to-creatinine ratio.

[^2]: Data are expressed as mean ± SD or absolute (n) and relative (%) frequency, unless otherwise indicated.

[^3]: Data are expressed as mean ± SD or absolute (n) and relative (%) frequency, unless otherwise indicated. DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NS, not significant; SBP, systolic blood pressure; U-ACR: urine albumin-to-creatinine ratio.

[^4]: BMI, body mass index; DBP, diastolic blood pressure; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; U-ACR: urine albumin-to-creatinine ratio.

[^5]: Data are expressed as mean ± SD or absolute (n) and relative (%) frequency, unless otherwise indicated.

[^6]: Albuminuria: (0) ACR \<30 mg/g creatinine; (1) ACR \>30 mg/g creatinine. Viral load: (0) copy number \<1000/ml blood; (1) copy number \>1000/ml blood. Gender: (0) female; (1) male. BMI, body mass index; CI, confidence interval; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; OR, odds ratio; SBP: systolic blood pressure.
